David Hwang

Mr. Hwang currently is Head of Corporate Development and Strategic Planning at Recipharm AB, a top 5 global CDMO. He is responsible for managing strategic investments, partnerships and mergers and acquisitions (M&A) globally. Mr. Hwang has more than 19 years of experience in corporate development, venture investment, corporate financing, and M&A and has worked on over $5 billion worth of transactions.

Prior to Recipharm, Mr. Hwang was Senior Director of Strategy and Corporate Development at Agilent Technologies and a Co-Founding Managing Director of Agilent’s Corporate Venture Capital team, where he served on the Board of Directors for Arima Genomics and Molecular Assemblies. He also held several senior roles at boutique investment banks in New York City and San Francisco. Mr. Hwang holds a BA from Brandeis University and an MBA from Rutgers University.